EASME

Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Brevel has developed an innovative cultivation technology focused on the sustainable and cost-effective production of microalgae. Utilizing high-tech, fully automated indoor systems that feature internal illumination, Brevel's approach achieves significant cost reductions and substantially higher yields compared to traditional methods. This advanced technology positions the company to tap into various markets in need of microalgae-derived products, including sustainable food, materials, chemicals, pharmaceuticals, and energy. By unlocking the full potential of microalgae, Brevel aims to create an alternative protein source suitable for mass production, addressing the increasing demand for environmentally friendly solutions across multiple industries.

Trovant Technology SL is a Spanish company based in Valladolid, established in 2018, that focuses on developing bio-based technologies for the treatment and valorization of organic waste. The company specializes in transforming waste into valuable products such as bioenergy and biomaterials. Its offerings include solutions for anaerobic digestion, biogas upgrading, biomethane production, wastewater treatment, bioindication, and bioinformatics. Trovant Technology aims to provide tailored solutions that address market needs while promoting environmental sustainability through innovative biotechnology products.

InterAx Biotech Ltd is a biotechnology company based in Villigen, Switzerland, focused on developing a platform for the discovery of functionally selective drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 2016, the company integrates bioanalytical methods and computational pharmacology to assist in drug candidate design and selection. Its innovative platform combines high-throughput biochemical screening with artificial intelligence and mathematical modeling of cell signaling, facilitating the identification and optimization of drug candidates for various diseases, including those associated with orphan GPCRs. Through its advanced approach, InterAx Biotech aims to improve drug efficacy while reducing side effects, contributing to the healthcare industry's efforts to discover safer and more effective treatments.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

CH-Bioforce provides a revolutionary technology for converting all biomass components into high-value material streams - dissolving pulp, polymeric hemicellulose, and sulphur-free lignin. These valuable biomaterials can replace fossil and food-based raw materials in multiple industries, such as textiles and packaging applications.

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of innovative hearing solutions tailored for individuals with varying degrees of hearing impairment. Originating as a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic Tübingen, Vibrosonic focuses on creating discreet hearing devices that integrate advanced microsystem technologies. Their unique approach involves the use of piezoelectric principles to design hearing contact lenses that can be directly placed on the eardrum. This technology transmits sound through vibrations rather than traditional speakers, enhancing the auditory experience while minimizing discomfort for users. Through its specialized equipment, Vibrosonic aims to improve the quality of life for those affected by hearing loss.

FGen GmbH, founded in 2011 in Basel, Switzerland, specializes in the development of a nanoliter-reactor platform for high-throughput phenotypic analysis of cellular libraries. This innovative approach facilitates the discovery and optimization of biological activities. As a contract research organization, FGen collaborates with partners in the biotechnology, life sciences, and pharmaceutical sectors to establish efficient bioprocesses and develop new biopharmaceuticals. The company also focuses on creating optimized microbial strains for various biotechnological applications, utilizing proprietary screening technology alongside biological engineering tools. This enables clients to achieve efficient and cost-competitive production of chemicals and proteins.

Toleranzia AB is a Swedish biotechnology company focused on developing innovative drugs that leverage the immune system to treat autoimmune orphan diseases. Unlike conventional treatments that primarily alleviate symptoms, Toleranzia's approach aims to address the root causes of these conditions, potentially offering cures or significant improvements in patient health. One of its key drug candidates, TOL2, is specifically designed for myasthenia gravis, an autoimmune neuromuscular disorder classified as an orphan disease. Through its targeted therapies, Toleranzia seeks to make a meaningful impact on the lives of patients suffering from these challenging conditions.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Mimetis Biomaterials SL is a Spanish company founded in 2013, specializing in the design and manufacture of biomimetic bone graft substitutes for medical applications in dental, craniomaxillofacial, and orthopedic sectors. The company focuses on creating synthetic bone grafting solutions that mimic the properties of natural bone, thereby facilitating the colonization of grafts by bone cells and improving outcomes in complex cases. Mimetis offers a range of products, including biomaterial granules and patient-specific 3D-printed grafts, to address various bone defect filling needs. In addition to its product offerings, the company provides consulting, original equipment manufacturing, and co-development services to clinicians. Mimetis Biomaterials was previously known as Subtilis Biomaterials S.L. until its name change in January 2016 and is headquartered in Barcelona, Spain.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

Planktovie specializes in creating and marketing nutritional solutions tailored for the maintenance of aquatic organisms. The company offers an online platform that provides optimal nutrient systems derived from phytoplankton and zooplankton, specifically designed for aquarium and aquaculture applications. Planktovie's products adhere to high standards necessary for the care of aquatic animal models, particularly benefiting the European zebrafish research community. Additionally, the company emphasizes sustainable practices in the exploitation of marine resources for biomedical research, aligning with the principles of the 3Rs—Replacement, Reduction, and Refinement—aimed at minimizing the use of animals in research.

WeedOut is a biotechnology company dedicated to developing innovative weed control solutions. The company focuses on creating bio-herbicides that utilize a unique approach to combat resistant weeds. By employing weed pollen and applying it during the flowering period through artificial pollination, WeedOut's products prevent the generation of viable seeds from these resistant weeds. This method aims to reduce reliance on toxic herbicides and minimize the application of higher herbicide doses, offering a natural alternative for farmers and stakeholders in the agricultural sector to effectively manage weed populations.

Zymvol accelerates the discovery & development of new industrial enzymes through computer simulations.

BioMensio Ltd. is a biotechnology company based in Tampere, Finland, established in 2015. It specializes in developing smart multi-analyte handheld detection devices for bio-analytics, providing rapid and on-site detection of various biological targets from a small sample in a single step. The company's offerings include a novel miniaturized micro-array platform that supports the quick development of new bio-screening applications, which are applicable in areas such as saliva testing, food and milk safety, point-of-care diagnostics, and bio-security. BioMensio's technology enables the creation of label-free assays, allowing for the detection of multiple analytes without the need for labeling procedures. Additionally, its Diagnostics-as-a-Service (DXaaS) platform integrates a handheld reader, multianalyte fluid cartridges, and cloud-based analytics, facilitating easier access for original equipment manufacturers (OEM) to develop bio-analysis products and services.

Bioithas is a biotechnology company dedicated to medical research. Its primary focus is the development of natural treatments that target the root cause of health issues, rather than just symptoms. The company conducts clinical trials in humans to test and validate its personalized treatments, aiming to enhance users' quality of life and overall well-being.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Vetherapy Corp., established in 2015 and headquartered in San Francisco, specializes in veterinary regenerative medicine and tissue engineering. The company produces stem cell therapy products for cats, dogs, and horses, focusing on accelerating wound healing and treating autoimmune and inflammatory diseases. Vetherapy's offerings include stem cell and platelet-rich plasma (PRP) banking services, ensuring veterinarians have access to safe and efficient products for various animal health conditions.

CreatSens develops a platform that provides paper-based creatinine and potassium potentiometric sensors solutions to the healthcare industry. It helps healthcare professionals to better manage the information that can be generated in primary care centers, doctor’s office or patient’s homes. CreatSens platform aims to improve the well-being of people by allowing the monitoring of relevant biochemical parameters of blood out of the lab. The biochemical and physical information will be integrated into a technological platform allowing an accurate prediction, early detection and better prevention of acute conditions from home. The company was founded in 2017 and is headquartered in Tarragona, Catalonia, Spain.

Polymer Factory, established in 2006 at the Royal Institute of Technology in Stockholm, Sweden, is a prominent supplier of advanced dendritic and polymeric materials, also offering contract research services. Its product range includes monodisperse dendritic polymers derived from 2,2-bis(methylol)propionic acid, such as biocompatible bis-MPA dendrimers and dendrons. The company specializes in the synthesis of high-quality macromolecules, custom materials, and calibrants for MALDI-ToF. Polymer Factory holds exclusive rights to produce, market, and sell several advanced materials, and it globally supplies polyester (Boltorn™) and polyester amide (Hybrane®) hyperbranched polymers for research purposes.

Nanografi, established in 2011 at METU Technopolis, has been at the forefront of graphene production, advanced materials and nanotechnology. In 2020, Nanografi launched the most efficient and largest graphene mass production facility, making it one of the pioneering companies in the world. For over a decade, Nanografi has remained a powerful solution partner in advanced material technologies. Operating under Ahlatcı Holding, Nanografi is committed to innovation and anticipates the future's technological advancements and needs. Since 2011, leveraging its experience in high-tech solutions across more than 100 countries, Nanografi takes pride in contributing to thousands of valuable research studies and technologies, guided by its developed technologies and scientific investigations. Nanografi, a leading player in present and upcoming sectors like advanced material technologies, high-security authentication, biotechnology, and smart packaging technologies, remains committed to creating value with its international quality standards.

Metys Pharmaceuticals is focused on developing MP-101, a small molecule drug designed to prevent and treat chemotherapy-induced peripheral neuropathy, a significant side effect of various cancer treatments. MP-101 acts as an orally-active modulator of glutamate signaling in the brain and spine, a mechanism that has been sought after for central nervous system drug development. The drug is a patent-pending non-racemic mixture of the enantiomers of dimiracetam, specifically formulated to enhance potency compared to traditional racemic mixtures. Metys Pharmaceuticals has secured exclusive global rights to racemic dimiracetam from Neurotune AG and aims to leverage existing pharmacological, toxicological, and clinical data to support future clinical trials for MP-101. Through its innovative approach, Metys Pharmaceuticals aims to provide effective treatments for neuropathic pain and improve patient outcomes in cancer care.

7scientists current academic research findings into practical solutions.

BIOsens Inc. specializes in developing biosensors for the rapid quantitative diagnostics of food toxins, particularly mycotoxins. The company offers a testing device that allows for easy sample preparation and delivers results within 15 minutes. These results are stored in the cloud, utilizing Internet of Things (IoT) technology. By providing efficient and reliable testing solutions, BIOsens aims to enhance food safety and help consumers trust the safety of their food products.

High Efficiency Water Condensing Biomembranes.ThinAir is tackling one of the three biggest problems on the planet, water scarcity. ThinAir has developed a bio-membrane that condenses water from air efficiently and energy-free. Inspired by the potential of biomimicry,they've harnessed the way beetles capture water even in the driest habitats in the world. The technology will facilitate agriculture and provide clean water for human consumption in areas where clean water is scarce.

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Their strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators,

Brain Stimulation AB is a Swedish small and medium-sized enterprise established in 2011, focusing on the assessment and rehabilitation of patients recovering from strokes and traumatic brain injuries. The company utilizes advancements in brain plasticity research to offer innovative rehabilitation solutions, particularly for cognitive impairments and attention disabilities, such as Spatial Neglect. By addressing the global need for effective rehabilitation in conditions like stroke, dementia, traumatic brain injuries, and Parkinson's disease, Brain Stimulation employs a concept known as Enriched Rehabilitation. Their approach combines precision diagnostics with individualized care technology, facilitating effective neurological rehabilitation that can be accessed remotely. This method aims to create a motivating rehabilitation environment that leads to proven and lasting improvements in patients' cognitive and motor functions, ultimately enhancing their recovery process.

Next Generation Sensors is a biotech business that creates mass spectrometers for commercial uses in the life sciences. Finding rapid, accurate screening information for potential health, security, and environmental hazards relies on. By bringing the lab to the sample with portable, sensitive, accurate, and user-friendly technology for quick detection of dangerous compounds in our food, bodies, and environment, offers answers for a safer future.

Inflection Biosciences Ltd. is a drug development company focused on discovering and developing small molecule therapeutics for cancer treatment. Founded in 2012 and based in Dublin, Ireland, with additional operations in London, the company aims to identify promising early-stage cancer research from academic institutions and other organizations globally. Its research pipeline includes innovative PIM kinase inhibitors and multi-targeting kinase inhibitors that are currently in preclinical development. With a team that combines over 60 years of industry experience, Inflection Biosciences is dedicated to advancing its most promising programs through early clinical stages, with plans to partner with larger pharmaceutical companies for later-stage development and commercialization. The company also explores therapeutics for autoimmune and inflammatory diseases, solid tumors, and hematological malignancies, striving to enhance treatment options for healthcare providers.

TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

BioCom is a highly innovative Company in the biomedical sector, focused on research, development and manufacture of cutting-edge medical devices, as well as the development of new technologies for surgery, diagnostics and biomedical research.

Mecwins specializes in developing advanced nanomechanical sensing technology to create sensitive immunoassays aimed at improving healthcare outcomes for individuals at risk for oncology, cardiovascular diseases, and infectious diseases. Their innovative platform combines nanomechanical sensing with plasmonic emission using a sandwich immunoassay approach, allowing for the production of ultrasensitive detection systems. This technology enables researchers to achieve enhanced sensitivity in disease detection, ultimately contributing to better diagnostics and treatment options in critical areas of healthcare.

MycoSolutions AG specializes in developing customized soil additives designed to protect and maintain trees, particularly veteran specimens. Based in St. Gallen, Switzerland, the company offers a range of services including the diagnosis of fungal pathogens, visual tree inspections, hazard assessments, and the development of tailor-made plant growth promoters. MycoSolutions is recognized as a technology leader in the efficient use of mushrooms, leveraging the expertise of its founders and employees to provide environmentally friendly alternatives to conventional wood preservatives and agricultural pesticides. The company's commitment to sustainability aims to reduce the environmental impact of harmful chemicals, while its educational initiatives include training sessions and publications to enhance knowledge in tree care and soil health.

ScarTec Therapeutics develops novel peptide-based technology for scar-free healing.

Ecohelix specializes in the production of innovative amphiphilic polymers derived from lignocellulosic side streams of the pulp industry. Utilizing a patented enzymatic process, the company transforms residual materials such as lignin and hemicellulose into high-performance, biodegradable polymers. Their flagship product, WOODMER®, serves as a sustainable alternative to conventional plastics and fossil-based materials, finding applications in packaging, adhesives, and paper chemicals. By harnessing underutilized raw materials, Ecohelix not only enhances the value of the pulp industry but also contributes to a more sustainable future by significantly reducing CO2 emissions and promoting environmentally friendly practices across various sectors, including packaging, construction, and cosmetics.

Eden Microfluidics is a young innovative company founded in 2017. The company aims to provide advanced and certified materials, microfabrication and microfluidics solutions to both researchers and industrial partners. Eden Microfluidics is driven by a team of talented and passionate scientists, innovators and entrepreneurs, thriving to develop radical microfluidic solutions, for biomedical to environmental challenges. All together, they assemble a large IP portfolio of polymer and epoxy formulations, cellular micro-environment and microfluidic remediation systems. Eden Microfluidics is here to offer you access to the latest, up-to-date microfluidic science and technology.

PreOmics GmbH, founded in 2016 and based in Planegg, Germany, specializes in mass spectrometry (MS)-based proteomics. The company develops innovative tools, including the iST Kit, designed for efficient sample preparation and peptide pre-fractionation, which allows researchers to process peptide mixtures in just one hour. PreOmics focuses on providing solutions for the identification of protein interaction partners, large-scale protein discovery, and quantification of proteins, as well as the analysis of post-translational modifications. As a spin-off from the Max-Planck Institute of Biochemistry, the company aims to enhance protein analysis for researchers worldwide by offering high-quality technologies that streamline and improve research outcomes.

Clarify Analytical is an innovative service providing start-up committed to develop state-of-the-art mass spectrometry based methodologies.

Clover Bioanalytical is a bioinformatics company that specializes in data processing for bioanalytical chemistry and clinical diagnostics applications, particularly utilizing mass spectrometry. Founded by a team of Ph.D. graduates with expertise in both business and research, the company focuses on developing advanced software and statistical analysis tools for the biomedical field. Clover’s capabilities extend beyond mass spectrometry to include medical image processing and both univariate and multivariate statistical analysis, addressing the challenges posed by Big Data. The company emphasizes a customer-oriented approach, aligning its solutions with the specific goals and scalability needs of its clients. By leveraging artificial intelligence, Clover aims to enhance the rapid identification of microorganisms, positioning itself as a key partner for hospitals, research institutions, and biotechnology companies in tackling significant scientific questions.

TransCure bioServices SAS, founded in 2012 and located in Archamps, France, specializes in vivo pharmacology preclinical services tailored for pharmaceutical, biotech, start-up, and academic researchers. The company offers unique research and development platforms, including the Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. These platforms are accessible as fee-for-service solutions, enabling clients to profile new drugs targeting immuno-related diseases and develop novel anti-HIV/AIDS therapies. By providing humanized mouse models that better predict human drug responses compared to traditional models, TransCure bioServices helps accelerate the development and commercialization of new drugs and therapies, facilitating a more efficient pathway for researchers to bring innovative treatments to market.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Amypore is focused on developing innovative therapies for Alzheimer's and Parkinson's diseases through its lead product, AmyP53. This chimeric peptide is created using an advanced artificial intelligence strategy applied to molecular neuroscience. AmyP53 targets a common mechanism in both neurodegenerative diseases by blocking the formation of neurotoxic structures, specifically oligomers of amyloid proteins, which are implicated in disease progression. As the first representative of a new therapeutic class, AmyP53 offers a unique approach to treatment, aiming to provide patients with effective solutions for conditions that currently lack adequate therapies.

300K is a biotechnology start-up composed of a multidisciplinary team with expertise in developing and commercializing innovative life sciences products and services. The company specializes in creating solutions for the storage and shipment of bio-specimens at room temperature. Its stabilization technology enhances the preservation of biological samples, ensuring a secure process while optimizing storage space in life science facilities. By enabling laboratories to stabilize biospecimens at room temperature, 300K aims to minimize sample loss and improve the overall efficiency of biosample management.

TomoWave is a company focused on developing innovative imaging technologies for clinical medicine and preclinical research. Utilizing its proprietary optoacoustic and laser ultrasonic imaging modalities, TomoWave aims to enhance cancer detection, guide medical interventions, and monitor the effectiveness of cancer therapies. The company's technology, which captures images by "listening to the sound of light," allows for highly detailed visualization of tissues, particularly in relation to vascular and blood-related conditions. Founded by Dr. Alexander Oraevsky, a pioneer in biomedical optoacoustics, TomoWave has a strong emphasis on generating intellectual property and advancing it from concept to validated clinical prototypes. The company is committed to bringing its technologies to market through appropriate regulatory certifications, thus contributing to improved diagnostic capabilities in healthcare.

FreezeM is focused on advancing preservation technologies that enhance the use of insects as a sustainable protein source for the animal feed industry. The company is developing innovative methods for large-scale freezing of insects, which will facilitate the creation of global stocks of frozen insect neonates and eggs. This approach aims to address critical challenges related to the availability, cost, and regulatory hurdles associated with utilizing insects in animal feed. By ensuring a stable and year-round production of these beneficial insects, FreezeM seeks to make a significant impact on the animal feed market, while also contributing to biological pest control and species preservation.

InProcess-LSP, founded in 2014 by former employees of MSD/Merck, operates from its facilities in Oss, The Netherlands, located within Pivot Park, a hub for innovative pharmaceutical and life-science companies. The company specializes in process analytical technology that offers real-time characterization of nanoparticles during various processes. By integrating advanced spectroscopic optical technologies with sophisticated chemometric modeling, InProcess-LSP provides solutions that enhance operational efficiency and process improvement for its clients in the pharmaceutical and life-sciences sectors.

Scandinavian ChemoTech AB is a clinical development company headquartered in Lund, Sweden. It specializes in cancer care and pain management solutions, primarily through its innovative product, IQWave. This electroporation device uses short electric pulses in conjunction with localized or intravenous chemotherapy to treat various cancers, including head and neck squamous cell carcinoma, malignant melanoma, and breast adenocarcinoma, among others. The company's founders bring extensive experience in surgical oncology and clinical research, driving its commitment to advancing cancer treatment through genuine research and clinical trials. ChemoTech markets its products via distribution channels and a network of opinion leaders across regions such as South East Asia, India, and the Philippines. Established in 2013, the company continues to focus on developing effective therapies for cancer patients.

Saphenus has decoded phantom pain and enlarge gait stability through the sense of touch idea and the findings of the medicine nobel price 2021. Globally, millions of amputees face the devastating challenge of phantom pain, with no effective solution available until now. This constant, debilitating pain significantly impacts their quality of life. Saphenus has developed a groundbreaking technology that not only decodes phantom pain but also enhances mobility and stability through an innovative sensory feedback system, redefining what prosthetics can achieve. The urgency of our approach is underscored by the ongoing crisis in conflict zones like Ukraine-Russia and Israel-Palestina. These individuals urgently need faster, pain-free, and effective prosthetic solutions. With the establishment of our partnership with Ternopil Medical University in 2024, Saphenus is uniquely positioned to bring its innovation to those who need it most, offering renewed hope and quality of life. https://www.ukrinform.ua/rubric-regions/3916291-u-ternopoli-vijskovi-otrimali-innovacijni-priladi-do-proteziv-vid-avstrijskoi-kompanii.html Our technology is not just a medical breakthrough but a humanitarian imperative, poised to transform the lives of millions worldwide. Saphenus was awarded 2024 from the European Institute of Technology as one of the 6 best medtech startups in Europe.

MIMETAS B.V., founded in 2013 and based in Leiden, the Netherlands, specializes in the development of microfluidics-based culture plates designed for the cultivation and screening of three-dimensional organ and tissue models. The company's product line includes OrganoPlate 2-lane and 3-lane systems, which facilitate early-stage screening for drug efficacy and toxic side effects. By addressing the discrepancies between traditional in vitro and animal models and actual patient responses, MIMETAS aims to enhance the predictability of drug testing. Its OrganoPlates enable high-throughput screening of customized disease, toxicology, and transport models, thereby providing researchers and clinicians with innovative tools for compound testing and fundamental research.

TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies. The Company’s principal technology is the CTPIC technology platform that utilizes a non-viral vector to target and destroy cancer cells that over-express certain receptors while simultaneously eliciting an immune response against the cancer cells.

Double Bond Pharmaceutical is a pharmaceutical company focused on developing and commercializing innovative treatments for cancers, infections, autoimmune diseases, and other life-threatening conditions. The company aims to address unmet medical needs by providing more efficient and safer therapeutic options for patients. Through its first-in-class approaches, Double Bond Pharmaceutical seeks to improve patient outcomes and contribute significantly to the healthcare market.

Beta Bugs is an insect genetics company focused on developing high-performance breeds of Black Soldier Fly for insect farmers. The company's primary mission is to enhance the productivity of the insect protein sector, making it competitive with traditional feed ingredients such as fishmeal and soymeal. To achieve this, Beta Bugs operates a breeding program called HiPer-Fly® and runs an egg production site known as The Multiplier®, supplying its breeds to both UK and international markets. By leveraging biotechnology and breeding techniques, Beta Bugs aims to establish a sustainable protein source that converts food waste into high-quality protein for use in livestock, aquaculture, and pet feed, thereby providing an alternative to conventional feed sources. The company is headquartered at the Easter Bush Campus, collaborating with the Roslin Institute, a leader in animal genetics.

Nanovex Biotechnologies SL is an innovative technology-based spin-off from the University of Oviedo founded in 2014 that provides a wide range of services and products in the nanobiotechnology field.

Surflay Nanotec focuses on functional surfaces, nanoscale coatings, polymers and microsensors. Their aim at Surflay is to rapidly deliver product-oriented scientific solutions to their customers and partners. They offer four inter-connected services: Contract research and surface solutions: surface modification and functionalization, Layer-by-Layer (LbL) coatings Fluorescent labeled polymers Nanostructures / Microstructures / Beads Microsensors: bioanalysis, pH, temperature & more

Kyanos specializes in the production of microalgae-based food products, focusing on sustainability and environmental health. The company employs an innovative process for cultivating high-value polysaccharides and pigments using high-output micro-algae in vertical photo-reactors. This patented technology significantly enhances productivity while minimizing environmental impact. Kyanos aims to provide consumers with sustainable and contaminant-free food options, thereby contributing to a healthier planet and promoting eco-friendly dietary choices.

Picterus is developing a smartphone application aimed at diagnosing jaundice in newborns, a condition that contributes to over 100,000 deaths annually, particularly in impoverished areas of Sub-Saharan Africa and South Asia. Existing screening devices are prohibitively expensive, often costing around $7,000, which limits access in low-resource settings. The app utilizes patented biomedical optics technology to provide accurate estimates of jaundice levels while accounting for variations in skin pigmentation. This innovation addresses the growing need for affordable and effective diagnostic tools, especially given the trend of shorter hospital stays post-birth and the rising rates of jaundice-related hospital readmissions. By enabling parents to monitor their child's jaundice levels at home, Picterus aims to improve health outcomes for vulnerable populations.

Probiomedica is a company focused on developing innovative biomedical devices that integrate engineering, biology, photonics, and robotics for health and personal care applications. The company specializes in creating small swallowable capsules designed to emit light at specific wavelengths, utilizing the principles of Photodynamic therapy. This technology aims to enhance the photo-killing of harmful bacteria such as Helicobacter pylori, which is associated with conditions like gastritis, peptic ulcers, and gastric cancer. By employing these advanced photonic techniques, Probiomedica seeks to offer effective treatments that minimize reliance on pharmaceuticals and reduce the risk of drug-related side effects, thereby improving patient outcomes in the realm of gastrointestinal health.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

BIA doo has consulting sales and technical support in the fields of biotechnology, chromatography, organic synthesis, sample preparation, laboratory equipment, and software for laboratories. It is a supplier of laboratory and process equipment.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

Seaweed Solutions AS is a seaweed cultivator and innovator established in 2009, focusing on large-scale ocean farming of seaweed for various applications, including food, feed, pharmaceuticals, and biomaterials. The company has established itself as a leader in European seaweed cultivation, controlling the entire value chain from proprietary seed hatcheries to processing plants. With a patented cultivation technology called Seaweed Carrier, Seaweed Solutions combines extensive knowledge in marine biology and engineering to pioneer modern seaweed farming practices. Its primary operations are based in Norway, where it manages the largest seaweed farms in Europe dedicated to brown macroalgae. The company's objectives include becoming the leading supplier of cultivated biological seaweed and seaweed seeds in Europe. Additionally, Seaweed Solutions forms partnerships and offers turnkey solutions related to cultivation technology, raw material sourcing, market development, and environmental services, thereby supporting sustainable practices in the seaweed industry.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in photonic biosensor technology. The company leverages patented innovations developed in TNO's Optics department to commercialize rapid, sensitive, and low-cost biosensors and instruments. These advanced biosensors utilize integrated photonics and optical chips containing waveguides that facilitate the transportation of light across multiple sensors. This technology enables real-time, label-free monitoring of biomarkers, allowing for accurate concentration measurements within minutes. Delta Diagnostics aims to enhance research in life sciences and facilitate the development of novel diagnostics through its innovative biosensing solutions.

Enzymlogic specializes in enzymology and protein science, offering analytical services aimed at enhancing drug discovery and development for the pharmaceutical and biotech industries. The company assists in identifying kinetic profiles during the drug development process, which helps clinicians understand the interactions between drugs and their targets. This insight is crucial for evaluating factors that influence efficacy and safety, ultimately contributing to the creation of innovative therapies that improve patients' quality of life. Enzymlogic aims to become a key resource for organizations focused on successful drug discovery, ensuring their clients achieve optimal returns on investment while advancing therapeutic solutions.

ProtectPipe is a Finnish microbiotechnology company producing an innovative microbe solution that removes organic waste from drainpipes. The microbe solution moves to the areas with build-up in the pipes and devours the waste. That is an ecological way to stop the erosion in pipes and prevent any harmful waste from entering the fragile environment.

InSCREENeX GmbH is a biotechnology company based in Braunschweig, Germany, founded by Dr. Roland Schucht as a spin-off from the Helmholtz Centre for Infection Research. The company specializes in cellular screening technologies aimed at accelerating the drug discovery process for pharmaceutical and drug development firms. By employing advanced genetic manipulation techniques, InSCREENeX develops innovative and user-friendly mammalian cell systems that serve as effective decision-making tools throughout the drug development pipeline. The company's offerings include the generation of specialized cell lines for primary screening and the design of physiologically relevant cell types for secondary screening and profiling, ultimately reducing the time and costs associated with biopharmaceutical drug discovery and validation.

Pre Diagnostics is a Norwegian diagnostic company specializing in the development of innovative in-vitro diagnostic (IVD) products aimed at the early detection of diseases, particularly neurodegenerative conditions like Alzheimer’s disease. The company leverages a proprietary approach based on the premise that specific diseases trigger unique systemic responses in macrophages, which can be measured through blood samples. By focusing on intracellular measurements of disease-specific biomarkers within blood cells, Pre Diagnostics aims to provide healthcare professionals with actionable insights for early diagnosis. Their commitment to creating patient-friendly solutions positions them as a potential leader in the field of early Alzheimer’s detection, utilizing established technologies to develop their biomarker products.

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Vulcur Medtech is a medical device development company based in Vanløse, Denmark, established in 2018. The company specializes in wound healing through its innovative VMT laser technology, which targets chronic wounds that are otherwise difficult to treat. This advanced device utilizes laser pulses that effectively eliminate biofilm-producing bacteria while preserving healthy human cells, promoting the body's natural healing process. By significantly reducing healing time, Vulcur Medtech enhances the quality of life for patients suffering from chronic wounds.

Algalif supplies astaxanthin products from microalgae, including ingredients and finished formulations. They help solve the nutritional needs of current and future generations through the development and delivery of sustainable microalgae ingredients. They also commercialize a range of immune-health ingredients, for use in food, beverages, nutraceuticals, sports nutrition, and personal care products.

Poly-Pico Ltd, based in Cork, Ireland, specializes in innovative fluid dispensing technology developed from five years of research at the University of Limerick. The company designs and manufactures solutions for both Life Science and Industrial applications, serving prominent institutions such as NASA and Harvard. As a leading microdispensing specialist, Poly-Pico focuses on research and development to create advancements in liquid handling, including contactless biology techniques like levitating microdrops and non-contact ultra-low volume acoustic dispensing. This core technology addresses challenges such as cross-contamination and dispenser clogging while minimizing wastage through the use of simple, disposable cartridges. Poly-Pico's multidisciplinary team possesses expertise in micro-fluidics, electronics, mechanical engineering, and biotechnology, allowing them to offer both standard and customized solutions tailored to meet precise dispensing needs.

Immunitrack specializes in an AI-based prediction and assessment platform aimed at supporting biotechnology and pharmaceutical companies. The company provides contracted research services that focus on predicting immune system reactions to various pharmaceuticals. By producing reagents for examining these immune responses, Immunitrack assists clients in the development of biologics and vaccines. Its work is instrumental in facilitating the creation of new therapeutic solutions within the pharmaceutical industry.

MaxWell Biosystems AG is an electronics and biotechnology company based in Zurich, Switzerland, dedicated to advancing neuroscience research and enhancing preclinical drug discovery. Founded in 2016, the company specializes in functional cell imaging platforms, most notably its MaxOne electrophysiology platform. This innovative system features a high-density microelectrode array with 26,400 electrodes and 1,024 low-noise readout channels, which allows for precise recording and stimulation of electrogenic cells in vitro. By enabling researchers to extract detailed single cell and network parameters, MaxWell's technology significantly accelerates the characterization of cellular functions, reducing the typical timeframe from several months to just a few weeks. This advancement aids in phenotypic screening as well as drug toxicity and efficacy testing.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.

Pila Pharma AB is a clinical stage biotech company based in Malmö, Sweden, focused on developing XEN-D0501, a potent and selective TRPV1 antagonist. This innovative compound is being investigated as a treatment for type 2 diabetes, obesity, and the rare painful condition known as erythromelalgia. XEN-D0501 has undergone testing in over 300 subjects during phase 1 and phase 2 trials, demonstrating a favorable safety profile in healthy volunteers and patients with various conditions, including overactive bladder disease and chronic cough. The compound has shown efficacy in improving glucose-stimulated insulin secretion in type 2 diabetics. Recent preclinical studies have completed successfully without any registered side effects, allowing XEN-D0501 to advance to longer clinical trials. In July 2022, Pila Pharma received US Orphan Drug Designation for this compound in the context of erythromelalgia.

Surgitate specializes in the manufacture of synthetic models aimed at enhancing the training experience for medical and veterinary students, as well as healthcare professionals such as nurses and obstetricians. The company produces a range of models, including synthetic skin, breast, and vascular components, designed to simulate realistic surgical procedures, including incision, dissection, and suturing. This hands-on practice enables users to develop their skills in a controlled environment. Founded by a materials engineer and a thoracic surgeon, Surgitate benefits from the expertise of its investors, Farplas, a leader in plastic automotive parts manufacturing, and Inovent, a pioneer in technology commercialization and seed funding in Turkey. Farplas provides essential support in process development and mass production, while Inovent facilitates connections with potential investors and assists in business and marketing strategies.

Natac specializes in the research, development, and sustainable manufacturing of plant extracts and natural origin ingredients. The company serves various sectors, including nutraceuticals, pharmaceuticals, food, animal nutrition, and cosmetics, by providing access to high-quality bioactive compounds. Committed to exceeding industry standards, Natac employs a proprietary analytical method, HABOID, to ensure the purity of its botanical products. Sustainability is a core principle of Natac's operations, as it systematically evaluates agricultural processes to identify areas for improvement and investment. By utilizing the whole plant, the company aims to minimize the environmental impact of its production methods. Natac is strategically located in Spain, where it houses its manufacturing, research and development, and quality assurance departments, ensuring adherence to European standards while also maintaining a presence in international markets.

Vetbiobank is a biotech company specializing in veterinary regenerative medicine. The company develops cell and tissue therapies aimed at enhancing animal health and care. In addition to its focus on veterinary applications, Vetbiobank also engages in human cellular and tissue therapies. It supplies veterinarians with clinical-grade cell and tissue products, thereby supporting medical and scientific needs within the veterinary field. Through its innovative approach, Vetbiobank aims to improve outcomes for animals by advancing regenerative medicine techniques.

Microbium is an R&D company specializing in custom microbiological detection protocols tailored for specific industrial samples. Founded to address the industry's challenges with microbial contamination, Microbium integrates closely with national laboratories and analytical organizations across Russia, Denmark, and Slovenia. The company offers solutions that go beyond conventional microbiological methods, providing rapid analysis suitable for various sectors. Additionally, Microbium has developed electronic devices capable of detecting and eliminating microorganisms in drinking water, wastewater, and products from the chemical and food industries. These devices automate the detection and counting of harmful bacteria, such as E. coli and coliforms, while employing bioremediation processes to effectively remove contaminants. This innovation not only helps users identify and mitigate contaminated areas but also contributes to reducing production costs and lowering the carbon footprint associated with industrial processes.

RemAb Therapeutics specializes in the development of polymeric glycoconjugate molecules aimed at addressing nosocomial infections. The company's innovative technology focuses on eliminating non-neutralizing natural antibodies that hinder the immune system's natural response and promote pathogen proliferation. By targeting these antibodies, RemAb Therapeutics seeks to provide medical practitioners with effective new strategies for both treating and preventing a range of pathological infections, enhancing patient outcomes in the process.

Chemicare is a biotechnology company established in December 2016, focused on the discovery and development of orphan drugs for patients with calcium-related genetic diseases. The company aims to improve the quality of life for individuals suffering from conditions such as Tubular Aggregate Myopathy, York Platelet Syndrome, and Stormorken Syndrome. Chemicare is dedicated to creating therapies that address the abnormal intracellular calcium levels characteristic of these rare diseases, enabling healthcare professionals to provide effective treatment options for affected patients.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

NapiFeryn BioTech specializes in extracting protein from waste streams generated during rapeseed oil production. The company employs innovative biorefinery technology that enables a more sustainable and efficient extraction process compared to traditional methods. This approach results in high-quality protein isolates and concentrates that serve as functional and nutritional alternatives to animal-derived proteins. NapiFeryn's products are versatile and can be utilized in a variety of applications, catering to the needs of oil mills and food producers seeking to develop sustainable bio proteins.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

PlumeSTARS is a specialized pharmaceutical company focused on drug delivery systems for the treatment of respiratory diseases. The company develops antibiotics specifically designed to address lung infections in patients with Cystic Fibrosis. By discovering novel orphan medicines and utilizing advanced technologies for various active pharmaceutical ingredients (APIs), PlumeSTARS aims to create innovative inhalation therapies that improve patient outcomes. Their commitment to developing effective treatments positions them as a significant player in the field of respiratory health.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

ImmuneBiotech AB, founded in 2013 and based in Lund, Sweden, specializes in the research and development of innovative microbiome therapeutics. The company focuses on creating novel probiotics derived from lactic acid bacteria and synbiotic formulations that aim to influence gut microbiota and immune system responses. ImmuneBiotech's therapeutic products include combinations of probiotics, prebiotics, and proteins, specifically designed to address various inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. By leveraging its online platform, the company seeks to enable healthcare professionals to prevent and treat autoimmune and other chronic inflammatory conditions effectively.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, enabling early intervention to prolong gestation and enhance neonatal health outcomes. Pregnolia serves pregnant women and gynecologists, aiming to ensure every woman experiences a happy, healthy, and informed pregnancy. The company's dedicated team, including Sabrina, Francisco, and Annette, is committed to completing clinical trials, navigating regulatory paths, and commercializing the device to support gynecologists in improving preterm birth risk assessment and management.

Calyxia specializes in the design and production of customizable, biodegradable microcapsules that protect active ingredients during industrial processes. These microcapsules, which range in size from one micron to 50 microns, are engineered to safeguard ingredients from degradation while ensuring their timely and targeted release. This innovative approach enhances the performance of formulations while promoting environmental sustainability by enabling the creation of products with fewer ingredients and improved efficacy. Calyxia's solutions cater to various industries, including advanced materials, sustainable agriculture, and home care, allowing companies to develop newly formulated products that meet modern performance and environmental standards.

Gedea Biotech AB, founded in 2015 and based in Lund, Sweden, focuses on developing an antibiotic-free treatment for vaginal fungal infections, a common issue affecting approximately 75% of women at some point in their lives. The company's key product, GA101, utilizes natural substances to lower vaginal pH, provide physical barrier protection, and inhibit biofilm formation. This innovative approach aims to offer a safe and effective solution for treating and preventing vaginal infections without the use of antibiotics. Gedea Biotech is committed to addressing women's health needs through its unique treatment options.

SagaNatura is an Icelandic biotech company that specializes in the development, production, and export of health products derived from premium Icelandic ingredients. The company focuses on the organic herb Archangelica Angelica and high-quality Astaxanthin, offering a range of consumer products that are safe, vegan-friendly, and of Icelandic origin. SagaNatura operates under two primary brands, SagaMedica, established in 2000, and KeyNatura, launched in 2014. The company aims to promote healthier lifestyles through its clean-label nutrition products, which address various health issues, including vision, skin health, energy, and concentration. By leveraging Iceland's pristine environment, SagaNatura is committed to providing high-quality health solutions that contribute to the well-being of consumers.

Martin and Co Ltd was funded, for providing different R&D services in the field of chemistry method development, biotechnological process development and analytical chemistry method developments. Their company is located at Berlini Park (http://www.berlinipark.hu/), which is an incubation space for chemistry related start-ups in Budapest (formal buildings of Medicinal Chemistry research Center, which was shut down 10 years ago). We have all necessary laboratory units, toolkits and devices to carry out their research. Regarding analytical chemistry, we have Shimadzu Mass Spectrometer-2020(CL) and excess to other analytical units at the campus of Berlini Park. In summer of 2017, after the completion of RAID SME Instrument Phase 1 project by Tonosoft Ltd, the RAID knowledge and rights were transferred to Martin and Co Ltd. The patent about RAID project was prepared and submitted by Martin and Co Kft in October 2017.

AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

Advanced Microfluidics, based in Ecublens, Switzerland, is a machinery manufacturing company that specializes in developing and producing high-end lab equipment components. Their primary focus is on automated liquid handling systems, which are designed to minimize cross-contamination and reduce internal volume, ensuring precise and efficient fluidic performance. The company's products cater to both laboratory and industrial sectors, providing solutions with no dead volumes.